CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Pluri Inc. - PLUR CFD

1.0587
5.36%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0326
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.030779%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.013666%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.1187
Open* 1.1187
1-Year Change* -33.01%
Day's Range* 1.0587 - 1.1287
52 wk Range 0.65-2.21
Average Volume (10 days) 30.38K
Average Volume (3 months) 1.47M
Market Cap 34.94M
P/E Ratio -100.00K
Shares Outstanding 32.66M
Revenue 321.00K
EPS -1.12
Dividend (Yield %) N/A
Beta 1.60
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 3, 2023 1.0587 -0.0600 -5.36% 1.1187 1.1287 1.0587
Feb 2, 2023 1.1187 0.0200 1.82% 1.0987 1.1187 1.0787
Jan 27, 2023 1.1187 -0.0299 -2.60% 1.1486 1.1586 1.1087
Jan 26, 2023 1.1287 0.0100 0.89% 1.1187 1.1287 1.1187
Jan 25, 2023 1.0887 0.0000 0.00% 1.0887 1.0887 1.0887
Jan 24, 2023 1.1586 0.0000 0.00% 1.1586 1.1686 1.1586
Jan 20, 2023 1.1586 -0.0400 -3.34% 1.1986 1.1986 1.1586
Jan 19, 2023 1.2286 0.0200 1.65% 1.2086 1.2585 1.1686
Jan 18, 2023 1.2785 0.0599 4.92% 1.2186 1.2785 1.2186
Jan 17, 2023 1.2585 0.0799 6.78% 1.1786 1.3285 1.1786
Jan 13, 2023 1.2086 0.1399 13.09% 1.0687 1.3984 1.0687
Jan 12, 2023 1.0288 0.0000 0.00% 1.0288 1.0687 1.0288
Jan 11, 2023 1.0088 -0.0200 -1.94% 1.0288 1.0288 1.0088
Jan 9, 2023 1.0288 0.0300 3.00% 0.9988 1.0588 0.9988
Jan 6, 2023 0.9986 0.0435 4.55% 0.9551 1.0288 0.9551
Jan 5, 2023 0.9550 -0.0299 -3.04% 0.9849 0.9850 0.9489
Jan 4, 2023 0.9987 0.0039 0.39% 0.9948 0.9988 0.9948
Jan 3, 2023 0.9916 0.0067 0.68% 0.9849 0.9985 0.9788
Dec 30, 2022 0.9352 -0.0065 -0.69% 0.9417 0.9489 0.9352
Dec 29, 2022 0.9277 -0.0175 -1.85% 0.9452 0.9551 0.9203

Pluri Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 2.847 0 0.05 0.054 0.023 0
Revenue 2.847 0 0.05 0.054 0.023 0
Cost of Revenue, Total 0.1 0 0.002 0.002 0 0
Gross Profit 2.747 0 0.048 0.052 0.023 0
Total Operating Expense 26.166 28.019 33.781 35.586 29.499 50.623
Selling/General/Admin. Expenses, Total 6.486 6.927 11.193 9.157 7.922 20.557
Research & Development 20.85 21.972 24.478 12.841 21.643 13.47
Depreciation / Amortization 2.006 2.029 1.893 1.841 1.453 1.252
Other Operating Expenses, Total -3.276 -2.909 -3.785 11.745 -1.519 15.344
Operating Income -23.319 -28.019 -33.731 -35.532 -29.476 -50.623
Interest Income (Expense), Net Non-Operating 0.109 0.272 8.542 0.105 0.356 0.781
Other, Net -0.036 -0.067 -0.937 0.12 -0.032 -0.023
Net Income Before Taxes -23.246 -27.814 -26.126 -35.307 -29.152 -49.865
Net Income After Taxes -23.246 -27.814 -26.126 -35.307 -29.152 -49.865
Net Income Before Extra. Items -23.246 -27.814 -26.126 -35.307 -29.152 -49.865
Net Income -23.246 -27.814 -26.126 -35.307 -29.152 -49.865
Income Available to Common Excl. Extra. Items -23.246 -27.814 -26.126 -35.307 -29.152 -49.865
Income Available to Common Incl. Extra. Items -23.246 -27.814 -26.126 -35.307 -29.152 -49.865
Diluted Net Income -23.246 -27.814 -26.126 -35.307 -29.152 -49.865
Diluted Weighted Average Shares 7.9548 8.74262 10.5877 1.23329 18.1973 28.1136
Diluted EPS Excluding Extraordinary Items -2.92226 -3.18143 -2.46759 -28.6283 -1.602 -1.77369
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -2.85237 -3.12149 -2.38995 -28.1158 -1.5688 -1.74709
Q3 2021 Q4 2021 Q1 2021 Q2 2021 Q3 2022
Total revenue 0 0 0 0 0.234
Revenue 0 0 0.234
Cost of Revenue, Total 0 0
Gross Profit 0 0
Total Operating Expense 14.225 14.587 11.441 10.795 10.709
Selling/General/Admin. Expenses, Total 6.559 6.102 5.088 4.288 4.553
Research & Development 7.824 8.507 6.391 6.541 6.273
Other Operating Expenses, Total -0.158 -0.022 -0.038 -0.034 -0.117
Operating Income -14.225 -14.587 -11.441 -10.795 -10.475
Interest Income (Expense), Net Non-Operating -0.029 0.019 0.009 -0.145 0.557
Net Income Before Taxes -14.254 -14.568 -11.432 -10.94 -9.918
Net Income After Taxes -14.254 -14.568 -11.432 -10.94 -9.918
Net Income Before Extra. Items -14.254 -14.568 -11.432 -10.94 -9.918
Net Income -14.254 -14.568 -11.432 -10.94 -9.918
Income Available to Common Excl. Extra. Items -14.254 -14.568 -11.432 -10.94 -9.918
Income Available to Common Incl. Extra. Items -14.254 -14.568 -11.432 -10.94 -9.918
Diluted Net Income -14.254 -14.568 -11.432 -10.94 -9.918
Diluted Weighted Average Shares 29.6172 31.6441 32.0008 32.1363 32.2616
Diluted EPS Excluding Extraordinary Items -0.48127 -0.46037 -0.35724 -0.34042 -0.30742
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.48127 -0.46037 -0.35724 -0.34042 -0.30742
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 35.596 29.016 32.036 26.371 48.461 67.371
Cash and Short Term Investments 32.208 26.106 29.9 23.705 45.784 64.95
Cash & Equivalents 6.223 4.707 8.821 4.106 8.27 31.241
Short Term Investments 25.985 21.399 21.079 19.599 37.514 33.709
Total Receivables, Net 2.481 1.174 0.847 1.421 1.61 1.49
Accounts Receivable - Trade, Net 2.251 1.036 0.69 1.243 1.248 1.108
Prepaid Expenses 0.3 0.882 0.602 0.532 0.445 0.333
Other Current Assets, Total 0.607 0.854 0.687 0.713 0.622 0.598
Total Assets 45.941 37.534 38.96 31.31 65.532 93.538
Property/Plant/Equipment, Total - Net 9.216 7.277 5.678 3.838 3.775 2.227
Property/Plant/Equipment, Total - Gross 17.183 16.507 16.893 17.004 18.437 18.259
Accumulated Depreciation, Total -7.967 -9.23 -11.215 -13.166 -14.662 -16.032
Long Term Investments 0.363 0.403 0.383 0.398 12.653 23.269
Other Long Term Assets, Total 0.766 0.838 0.863 0.703 0.643 0.671
Total Current Liabilities 5.775 5.414 8.548 8.158 7.987 11.517
Accounts Payable 2.705 1.966 3.261 2.281 1.968 2.526
Accrued Expenses 2.819 3.106 4.164 5.637 5.893 8.951
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 0.251 0.342 1.123 0.24 0.126 0.04
Total Liabilities 7.785 7.283 10.453 9.489 9.431 36.387
Total Long Term Debt 0 0 0 0 0 23.85
Other Liabilities, Total 2.01 1.869 1.905 1.331 1.444 1.02
Total Equity 38.156 30.251 28.507 21.821 56.101 57.151
Common Stock 0.001 0.001 0.001 0.001
Additional Paid-In Capital 198.432 217.822 244.203 272.824 336.257 387.172
Retained Earnings (Accumulated Deficit) -161.757 -189.571 -215.697 -251.004 -280.156 -330.021
Unrealized Gain (Loss) 1.48 1.48 8.44
Other Equity, Total 0 0.519 -8.44
Total Liabilities & Shareholders’ Equity 45.941 37.534 38.96 31.31 65.532 93.538
Total Common Shares Outstanding 8.0269 9.69388 11.3566 15.0829 25.4927 31.9578
Long Term Debt 23.85
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 49.82 67.371 62.826 60.153 64.313
Cash and Short Term Investments 47.37 64.95 60.671 58.183 61.98
Cash & Equivalents 12.265 31.241 14.611 18.715 23.791
Short Term Investments 35.105 33.709 46.06 39.468 38.189
Other Current Assets, Total 2.45 2.421 2.155 1.97 2.333
Total Assets 79.174 93.538 83.747 81.184 79.127
Property/Plant/Equipment, Total - Net 2.713 2.227 1.749 9.331 9.14
Long Term Investments 25.937 23.269 18.483 10.965 4.235
Other Long Term Assets, Total 0.704 0.671 0.689 0.735 1.439
Total Current Liabilities 9.916 11.517 10.365 9.595 7.822
Accounts Payable 2.11 2.526 3.723 4.058 3.942
Accrued Expenses 5.613 6.575 6.642 5.537 3.88
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 2.193 2.416
Total Liabilities 11.038 36.387 34.84 41.344 41.034
Total Long Term Debt 0 23.85 23.444 23.158 22.924
Other Liabilities, Total 1.122 1.02 1.031 8.591 8.238
Total Equity 68.136 57.151 48.907 39.84 38.0933
Additional Paid-In Capital 383.589 387.172 390.36 392.233 400.351
Retained Earnings (Accumulated Deficit) -315.453 -330.021 -341.453 -352.393 -362.258
Total Liabilities & Shareholders’ Equity 79.174 93.538 83.747 81.184 79.1273
Total Common Shares Outstanding 31.7402 31.9578 32.0969 32.2251 32.3424
Total Receivables, Net 0
Accounts Receivable - Trade, Net 0
Current Port. of LT Debt/Capital Leases 0
Long Term Debt 23.85 23.444 23.158 22.924
Common Stock 0.00032 0.00032
Other Equity, Total -0.00032
Minority Interest 2.05
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -23.246 -27.814 -26.126 -35.307 -29.152 -49.865
Cash From Operating Activities -18.522 -21.611 -21.38 -29.453 -26.369 -30.91
Cash From Operating Activities 2.15 2.177 2.018 1.962 1.57 1.37
Non-Cash Items 3.498 4.174 -1.025 5.146 2.562 13.968
Cash Taxes Paid 0.066 0.028 0.027 0.01 0.01
Changes in Working Capital -0.924 -0.148 3.753 -1.254 -1.349 3.617
Cash From Investing Activities 1.312 4.355 5.681 1.17 -30.458 -7.265
Capital Expenditures -1.75 -0.378 -0.342 -0.239 -0.27 -0.373
Other Investing Cash Flow Items, Total 3.062 4.733 6.023 1.409 -30.188 -6.892
Cash From Financing Activities 0.807 15.797 19.921 23.582 60.87 61.402
Issuance (Retirement) of Stock, Net 0.807 15.728 19.833 23.475 60.87 36.953
Net Change in Cash -16.403 -1.459 4.222 -4.701 4.043 22.609
Financing Cash Flow Items 0.069 0.088 0.107 0
Issuance (Retirement) of Debt, Net 24.449
Foreign Exchange Effects -0.618
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -35.297 -49.865 -11.432 -22.372 -32.29
Cash From Operating Activities -21.313 -30.91 -8.789 -18.652 -28.074
Cash From Operating Activities 1.034 1.37 0.337 0.664 0.915
Non-Cash Items 10.382 13.968 3.188 6.1 7.782
Cash Taxes Paid 0.008
Changes in Working Capital 2.568 3.617 -0.882 -3.044 -4.481
Cash From Investing Activities -12.057 -7.265 -7.24 7.075 14.738
Capital Expenditures -0.331 -0.373 -0.015 -0.044 -0.081
Other Investing Cash Flow Items, Total -11.726 -6.892 -7.225 7.119 14.819
Cash From Financing Activities 36.992 61.402 0 0 7.5
Issuance (Retirement) of Stock, Net 36.992 36.953 0 0 0
Net Change in Cash 3.622 22.609 -16.62 -12.616 -6.908
Issuance (Retirement) of Debt, Net 24.449
Foreign Exchange Effects -0.618 -0.591 -1.039 -1.072
Financing Cash Flow Items 7.5
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Yanay (Yaky) Individual Investor 3.2937 1075620 396790 2022-12-22 LOW
Regals Capital Management, L.P. Investment Advisor 3.2824 1071938 1071938 2022-01-24
Aberman (Zalman) Individual Investor 2.5434 830604 -2000 2022-12-20 LOW
Slager (David M) Individual Investor 1.8774 613100 613100 2022-01-24 HIGH
Meitav Dash Investments Ltd. Investment Advisor 0.5132 167593 0 2022-09-30 LOW
Nia Impact Capital Investment Advisor 0.4071 132947 -318394 2022-09-30 LOW
Susquehanna International Group, LLP Investment Advisor 0.3235 105657 -174105 2022-09-30 LOW
Renaissance Technologies LLC Hedge Fund 0.3197 104400 -2900 2022-09-30 HIGH
Bridgeway Capital Management, LLC Investment Advisor 0.3142 102600 -10000 2022-09-30 LOW
Nikko Asset Management Americas, Inc. Investment Advisor/Hedge Fund 0.2574 84056 -20865 2021-12-31 LOW
Franco-Yehuda (Chen) Individual Investor 0.225 73466 6875 2022-12-21 LOW
Green Alpha Advisors, LLC Investment Advisor 0.1794 58603 2377 2022-12-31 HIGH
Values First Advisors, Inc. Investment Advisor 0.1398 45653 -2677 2022-12-31 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.1211 39544 0 2022-12-31 LOW
Jane Street Capital, L.L.C. Research Firm 0.1102 35986 -46524 2022-09-30 HIGH
Group One Trading, L.P. Research Firm 0.0877 28638 -5900 2022-09-30 HIGH
Zürcher Kantonalbank (Asset Management) Bank and Trust 0.0842 27497 -137 2022-12-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.0771 25169 0 2022-09-30 LOW
Millennium Management LLC Hedge Fund 0.0625 20412 -120303 2022-09-30 HIGH
Archford Capital Strategies, LLC Investment Advisor 0.0401 13091 0 2022-12-31 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+485000+

Traders

65000+

Active clients monthly

$48000000+

Monthly investing volume

$28000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Pluri Inc. Company profile

About Pluristem Therapeutics Inc.

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Financial summary

BRIEF: For the six months ended 31 December 2021, Pluristem Therapeutics Inc. revenues was not reported. Net loss increased 6% to $22.4M. Higher net loss reflects General and administrative expenses increase of 30% to $4.8M (expense), Stock-based Compensation in SGA increase of 9% to $4.6M (expense), Research & Development Expense decrease of 75% to $72K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.82 to -$0.70.

Equity composition

Common Stock $0.00001 Par, 01/13, 100M auth., 58,333,206 issd. Insiders control 11.74%. IPO: NA. 11/07,1-for-200 reverse stock split. 11/07, Name changed from Pluristem Life Systems, Inc. 12/07, Exchanged changed from OTC Bulletin Board to NASDAQ.

Industry: Biotechnology & Medical Research (NEC)

MATAM Advanced Technology Park
Building #5
3508409

Income Statement

  • Annual
  • Quarterly

People also watch

Natural Gas

2.46 Price
+2.120% 1D Chg, %
Long position overnight fee -0.1117%
Short position overnight fee 0.0782%
Overnight fee time 22:00 (UTC)
Spread 0.005

US100

12,476.10 Price
-0.850% 1D Chg, %
Long position overnight fee -0.0184%
Short position overnight fee 0.0072%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

22,939.20 Price
+0.010% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

Oil - Crude

74.15 Price
+0.860% 1D Chg, %
Long position overnight fee -0.0222%
Short position overnight fee 0.0064%
Overnight fee time 22:00 (UTC)
Spread 0.03

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading